Synergistic anti-tumor effect of 13-cRA and IFN-alpha/beta in mouse renal cell carcinoma

Int J Oncol. 1998 Jul;13(1):145-9. doi: 10.3892/ijo.13.1.145.

Abstract

The synergistic anti-tumor effect of 13-cis retinoic acid (13-cRA) and interferon-alpha/beta (IFN-alpha/beta) was investigated using a highly metastatic mouse renal cell carcinoma cell subline (RenCa/F). Although 13-cRA inhibited tumor growth in vivo as well as in vitro, IFN-alpha/beta did not. Combined administration of 13-cRA and IFN-alpha/beta significantly enhanced the anti-tumor effect of 13-cRA. The retinoic acid receptor (RAR)-alpha and RAR-gamma were expressed in RenCa/F cells. Treatment with IFN-alpha/beta did not influence the expression level of these receptors at the mRNA level, which suggests that the synergism of 13-cRA and IFN-alpha/beta is not mediated through the RAR.

MeSH terms

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • Carcinoma, Renal Cell / metabolism*
  • Drug Synergism
  • Female
  • Interferon-alpha / pharmacology*
  • Interferon-beta / pharmacology*
  • Isotretinoin / pharmacology*
  • Kidney Neoplasms / metabolism*
  • Lung Neoplasms / secondary
  • Mice
  • Mice, Inbred BALB C
  • RNA, Messenger / metabolism
  • Receptors, Retinoic Acid / genetics
  • Receptors, Retinoic Acid / metabolism
  • Retinoic Acid Receptor alpha
  • Retinoic Acid Receptor gamma
  • Tumor Cells, Cultured

Substances

  • Interferon-alpha
  • RNA, Messenger
  • Rara protein, mouse
  • Receptors, Retinoic Acid
  • Retinoic Acid Receptor alpha
  • Interferon-beta
  • Isotretinoin